The aim of this study was to evaluate the role of interstitial radiosurgery (IR) using the photon radiosurgery system (PRS) in the treatment of selected tumors within the thalamus and the basal ganglia. The PRS is a miniature X-ray generator that was developed for interstitial irradiation. This series included 14 patients (5 with glioblastomas, 4 with low-grade astrocytomas and 5 with metastases) harboring spheroidal lesions with dimensions ranging from 13 to 42 mm (mean 30 mm). After stereotactic biopsy, a radiation dose ranging from 6 to 15.4 Gy (mean 11.3 Gy) was delivered at the target volume margins. Follow-up varied from 3 to 26 months (mean 10.2 months). In the group of glioblastomas, 3 patients died (3-12 months after
Introduction
The treatment of low-grade or anaplastic glial tumors and metastatic lesions in the thalamus and basal ganglia, being in the circumferential neighborhood of critical structures, represents a challenging issue in neurosurgery. For this reason, in recent years, stereotactic radiosurgery has expanded as a minimally invasive treatment modality for such deep brain tumors. Radiosurgical techniques based on the use of external beams require a preventive histological diagnosis, in addition to large and expensive facilities. On the other hand, interstitial irradiation with radioactive isotopes involves the inconvenience of having to handle radioactive sources.
Interstitial radiosurgery (IR) using the photon radiosurgery system (PRS; Photoelectron Corporation, Waltham, Mass., USA) has recently been employed for the treatment of brain tumors [1] [2] [3] . Compared to brachytherapy, PRS IR eliminates the inconveniences of isotopes and presents dosimetric advantages, such as adjustable dose rate and steeper dose gradient; moreover, this portable device, compared to external radiosurgical systems, represents a cost-effective way to deliver IR immediately after the tumor biopsy -which is the legal basis for treatment decision -without requesting particular radiation protection measures or dedicated facilities [4] [5] [6] . In our institution, since January 2000, we have introduced the use of PRS IR in the minimally invasive treatment of selected tumors (spheroidal, glial or metastatic lesions). It has represented an alternative to conventional neurosurgery treatment when the risk-benefit ratio due to tumor localization was unfavorable or when such an option was requested by the patient. It Gallina/Francescon/Cavedon/Casamassima/ Mungai/Perrini/Russo/Di Lorenzo has also represented an alternative to external radiosurgery considering the advantage of having histological sampling and therapy in the same session, which permits, for patients with a limited prospect of survival, a benefit in terms of quality of life. Moreover, the steep dose gradient was a reason for the choice of PRS IR in cases of lesions in contact with critical structures. In this study, we report our experience with PRS IR in a subgroup of 14 patients harboring tumors, of appropriate size and shape, in the thalamus and the basal ganglia.
Patients and Methods

Patient Population
Between January 2000 and December 2001, after the Florence Ethical Committee approved the study, 30 patients who gave informed consent were enrolled in our protocol for PRS IR; 14 of them (7 male and 7 female patients), whose ages ranged from 17 to 77 years (mean age 56.5 years) had a tumor in the thalamus or in the basal ganglia. At the time of the treatment, all patients presented a good general condition with a Karnofsky Performance Scale rating equal to or greater than 70, and 6 had mild neurological deficit. All patients underwent contrast-enhanced computerized tomography (CT) scan and/or magnetic resonance (MR) imaging. The lesions were spheroidal in shape, with dimensions ranging from 13 to 42 mm (mean 30 mm) for maximum diameter. The clinical, histological and anatomic data of each patient are summarized in table 1.
Interstitial Radiosurgery Technique
The device has been described in previous reports [4, 7] . Briefly, PRS consists of a miniature X-ray generator that emits low-energy X-rays from the tip of a 10-cm-long, 3.2-mm-thick needle-like probe. The accelerating potential can be chosen between 30, 40 and 50 kV, giving an average photon energy ranging from about 15 to about 20 keV. Four values of beam current can be used (5, 10, 20 or 40 ÌA). The typical dose rate in water at 10 mm from the effective point of X-ray emission is 1.5 Gy/min using the 20-ÌA current. The dose gradient at the same point is typically 25% per mm for 50-kV X-rays, and the dose rate as a function of distance from the source is approximately proportional to 1/r 3 .
PRS IR is an image-guided stereotactic procedure. We use the F.L. Fischer stereotactic system with a Zamorano-Dujovny localizing unit and the Striker neuronavigation system STP 4.0 (Howmedica Leibinger, Freiburg, Germany). The procedure is performed in one session under local anesthesia supplemented by intravenous sedation. Steroid and anticonvulsant therapy is started 3 days before the procedure. A CT scan for the stereotactic targeting is acquired the day of the surgical procedure, following a specific protocol. These images are imported into the neuronavigation system for the treatment planning. A previously acquired MR imaging study of the patient is correlated with the CT images using the surface-matching algorithm supported by our neuronavigation software. Taking advantage of the whole imaging information, a segmentation of relevant structures and trajectory planning are performed. The first phase of the procedure consists of a stereotactic conventional biopsy for the histological diagnosis. Then, with the use of a dummy probe, an accuracy check on the simulator integrated into the F.L. Fischer system is performed. In particular, we verify and correct any possible displacement caused by the weight of the device (displace- Gallina/Francescon/Cavedon/Casamassima/ Mungai/Perrini/Russo/Di Lorenzo ments were observed in the range of 0-2 mm). The radiation source is then mounted on a self-modified stereotactic arc. The probe is introduced through the hole of the biopsy and moved forward so that the effective point of X-ray emission reaches the target coordinates. The irradiation treatment is then started. Patients receive a single intravenous dose of 8 mg of dexamethasone immediately before the radiation dose is delivered.
Treatment Strategy and Irradiation Parameters
Because of the nearly spherical shape of the PRS dose distribution, the effective point of X-ray emission has to be positioned at the geometrical center of the lesion. This point coincided with the one selected for the biopsy in the case of low-grade astrocytomas and in three patients with metastases, whereas in patients with malignant gliomas and in the remaining patients with metastases, the histological sample was obtained at a more adequate point. In order to define the planning target volume, both the tumor extension and the proximity of critical structures must be taken into account. In the case of metastatic lesions and low-grade gliomas, the target volume coincided with the tumor itself plus a 1-to 2-mm margin, while in the case of anaplastic gliomas, a wider margin (up to 4 mm) was used due to the infiltrative nature. Nevertheless, dose constraints were necessarily assigned to critical structures in some cases, resulting in lower doses to the tumor margin than desired. The radiation dose at the margins of the target volume ranged between 6 and 15.4 Gy (mean 11.3 Gy). A relative biological effectiveness factor ranging from 1.2 (50 kV) to 1.5 (40 kV) was taken into account during the dose prescription process [8] . The employed beam current was 20 ÌA and the irradiation procedure took between 10 and 42 min (mean 33 min). The irradiation parameters for each treatment are reported in table 1.
Results
When no complications were observed, patients were discharged after 2 days with a prescription of steroids and anticonvulsants. Patients were scheduled for clinical checks and imaging studies with contrast-enhanced CT scan and/or MR imaging 1, 3, 6 and 12 months after the treatment and at 6-month intervals thereafter. Clinical evaluation was obtained through Karnofsky Performance Scale rating. All imaging studies were reviewed during a multidisciplinary meeting attended by neurosurgeons, radiation oncologists and neuroradiologists at scheduled controls. An image integration between preoperative and follow-up CT and/ or MR imaging studies made it possible to compare the target volume with the corresponding volume on the control images. Reduction or stabilization of the tumor size was assessed as local control, whereas increase of the tumor size was considered a treatment failure.
No postoperative mortality was observed. The procedure was well tolerated in 10 patients. One patient who presented acute, severe neurological deterioration recovered after the positioning of a temporary external ventricular drainage. Two patients experienced transient mild neurological deterioration that resolved with steroids; 1 month after the treatment, another patient developed hydrocephalus necessitating the positioning of a ventriculoperitoneal shunt and long-term application of steroids.
Follow-up ranged from 3 to 26 months (mean 10.2 months). In the group of glioblastoma, 3 patients died (between 3 and 12 months after the procedure) due to tumor progression. Two patients (follow-up 3-5 months) are well and imaging shows tumor control ( fig. 1 ). In the group of metastases, 2 patients died because of systemic disease progression (4-9 months after PRS IR) and 3 are alive and in good condition (3-8 months after treatment). Local control of metastases was achieved in all cases ( fig. 2) . The 4 patients with low-grade astrocytomas (followup 15-23 months) are well and imaging studies show tumor control (fig. 3) . The results are summarized in table 1.
Discussion
In noncritical areas, radical surgery alone, in the case of low-grade astrocytomas, and radical surgery followed by whole-brain radiotherapy, in the case of anaplastic glial and secondary tumors, are still the gold standard [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . On the other hand, when such lesions involve the basal ganglia or the thalamus, the surgical treatment, in spite of using computer-assisted volumetric resection techniques, is still very challenging [20] [21] [22] [23] .
Stereotactic radiosurgery with external beams has proved to be highly effective in the case of metastases of adequate dimensions and is considered the option of choice for deep-seated lesions [24] . On the other hand, in the case of malignant gliomas, the role of radiosurgery seems to be less well defined. Even though some authors consider radiosurgery an important additional treatment in the management of malignant gliomas, significant benefits remain to be shown [25] [26] [27] [28] . Interstitial irradiation using isotopes in the case of low-grade gliomas has been extensively used and is considered a specific and effective treatment for selected patients with deep-seated lesions for whom surgery does not provide a curative treatment [29, 30] . PRS has operational and dosimetric characteristics that combine the advantages of external beam radiosurgery (short treatment time) with the advantages of interstitial radiosurgery (intratumoral placement of the radiation source); further, it does not present the inconveniences of these two treatment modalities. The first study on PRS IR was reported by Cosgrove et al. [1] in 1997, and presented preliminary results concerning their initial validation experience. In a subsequent work, the same authors presented their results in a larger series of patients, confirming a high local control rate in selected tumors [2] . We introduced PRS IR as a therapeutic option in the context of a modulated program for the management of brain tumors. In our experience, PRS proved to be easy to handle and reliable, even if its use requires a relatively long learning phase. Radia- tion exposure level measurements in the environment during PRS IR have demonstrated that only minimal radiation protection measures are needed [3] .
No experiments on PRS IR for lesions in the thalamus or in the basal ganglia have yet been reported in the literature. PRS has dose delivery characteristics that might be advantageous in the treatment of lesions for which the surgical approach is very delicate, being in the neighborhood of critical structures. The purpose of IR, either with isotopes or PRS, is to deliver a necrotizing dose of radiation accurately defined by means of image-guided stereotaxy. The dose delivered to the target tissue must have an extremely steep gradient, thus minimizing the dose on the surrounding tissue. In all our cases, the expected radiobiological effect was found as an expanding progressive central necrosis surrounded in some cases by a well-defined peripheral contrast-enhanced ring, as seen on MR imaging controls. The advantage of PRS IR compared to both isotopes and external radiosurgery is the steeper dose gradient, which can be varied via the accelerating potential. For example, at 10 mm from the source, it can be as high as 35% per mm, whereas with linac radiosurgery, values of 15% per mm are generally achievable with a 20-mm-diameter circular collimator. Recent technology has provided micro-multileaf collimators to be coupled to linac accelerators, with which highly conformed isodose surfaces can be achieved; nevertheless, the dose gradient remains comparable with that obtained with circular collimators.
In this series, postoperative mortality was nil and the procedure proved to be well tolerated and safe, although not completely free from complications. In the absence of surgical incidents detected on postoperative CT scan, complications such as transient neurological deterioration can be attributed to an increase of edema. Such events are also reported with conventional radiosurgery. An additional traumatism in PRS IR might be caused by the repeated introduction of the instruments, i.e. biopsy instrument and radiation source probe. In fact, postoperative T1-weighted MR images show in some cases a thin striation of contrast enhancement that marks the probe path from the point of introduction to the target.
Because of the limited number of treated patients and the short follow-up, at the moment it is not possible to draw a firm conclusion about the clinical value of PRS IR; however, from our experience, the results seem to depend on tumor histology [3] . In malignant glial tumors, PRS IR allowed local control just for a limited span of time. MR imaging controls after the treatment presented characteristic patterns, i.e. a spherical well-delimited area of hypointensity (whose shape and dimensions were consistent with the treatment parameters) surrounded by a ring of enhancement. At 3-6 months of follow-up, a centrifugal tumor proliferation was observed departing from the periphery of the treated volume and corresponding to the deterioration of clinical condition. Pathological studies on postmortem specimens showed, in the region corresponding to the treated volume, a spherical area of coagulative necrosis involving both vascular net and parenchyma that was sharply demarcated at the periphery from the area of apparently undamaged viable tumor invading the surrounding tissue. Indeed, with respect to highly malignant lesions infiltrating the nervous tissue at a distance, PRS IR seems to present the same limits of other conventional radiosurgical treatments. However, the potentialities of PRS IR alone or associated with adjuvant wholebrain radiotherapy in the field of malignant glial tumors in the thalamus and basal ganglia have yet to be determined since this treatment seems to compare favorably with surgery, due to its minor morbidity. Stereotactic fractionated radiotherapy has a role in the treatment of malignant gliomas [31] , but its positioning accuracy is poorer and its dose gradient is less steep compared to those of PRS [32] .
Histologically, low-grade astrocytomas are lesions with little spread of tumor cells into the periphery. These characteristics correspond to a good target for interstitial irradiation. According to Kreth et al. [29] , whose study involved 455 patients, interstitial irradiation with isotopes is a specific treatment modality for selected patients with unifocal circumscribed low-grade gliomas with a diameter of less than 4 cm in any location. No experiences are reported in the literature regarding PRS IR for the treatment of low-grade gliomas. The dosimetric characteristics of the device allow us to obtain well-defined small volumes of tissue necrosis, with less dose to the normal tissue outside the target. These characteristics, added to the substantial advantage of avoiding all the associated problems related to handling radioactive sources, represent the potential of PRS IR in the management of low-grade astrocytomas not suitable for surgical excision.
Metastases are ideal targets for radiosurgical treatment because of their shape and their demarcation from the surrounding normal tissue. Our experience using PRS IR with metastases confirms the good results achieved by Cosgrove et al. [2] . In the case of single lesions of adequate dimensions in which a biopsy is needed, PRS IR presents the appeal of making a diagnosis and applying the therapy in one single session.
Conclusion
PRS IR is an innovative therapeutic modality in the context of a modulated program for the management of brain tumors. This minimally invasive procedure represents an alternative and cost-effective means for the treatment of glial and secondary tumors spheroidal in shape and of adequate dimensions that are not candidates for conventional neurosurgical treatment and that necessitate a histological diagnosis. PRS presents dose delivery characteristics that can be advantageous in the treatment of lesions localized in the thalamus or in the basal ganglia. While larger case series are necessary in order to assess the clinical efficacy of this treatment modality, PRS IR seems to provide a high local control rate in metastases, while in the case of malignant gliomas, it shows low benefit. Low-grade astrocytomas could represent ideal targets for PRS IR if our results are confirmed by longer follow-up.
